Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biosimilarity Margin Change By FDA Might Give Amgen's Avastin Copy Big Head Start

Jul 20 2017

• By Derrick Gingery

T-cells attacking cancer_1200x675

Related Content

US Biosimilars: 40% First-Cycle Approval Rate Leaves Room For Improvement

Jul 06 2017

Mylan, Amgen Biosimilars Sail Through Advisory Panels, May Diverge From There

Jul 14 2017

Mylan's Herceptin Advisory Committee May Be First Bumpy One For A Biosimilar

Jul 12 2017

Amgen's Avastin Biosimilar May Revive Orphan Indication Concerns

Jul 12 2017

Pending Biosimilars

Feb 13 2017

Draft ‘Cures’ Bill Allows Advance Accelerated Approval Agreements

Apr 30 2015

Biosimilars Education: Oncobiologics/Premier Deal Aims To Boost Adoption, Data Collection

Mar 03 2016

Next Biosimilars Hurdle: Winning Over Physicians

Oct 06 2015

Related Companies

Genentech, Inc.

Amgen, Inc.

Allergan plc

Pfizer Inc.

Outlook Therapeutics, Inc.

Viatris Inc.

Biocon, Ltd.

Johnson & Johnson

Additional Topics

United States Biosimilars Advisory Committees Clinical Trials Regulation FDA BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window